Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cytodyn Inc
(OP:
CYDY
)
0.1265
UNCHANGED
Streaming Delayed Price
Updated: 3:59 PM EDT, Aug 26, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cytodyn Inc
< Previous
1
2
3
4
Next >
CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
January 25, 2022
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
January 13, 2022
From
CytoDyn Inc.
Via
Business Wire
Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
January 10, 2022
From
CytoDyn Inc.
Via
Business Wire
Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
January 05, 2022
From
CytoDyn Inc.
Via
Business Wire
Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant
December 29, 2021
Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The...
Via
Benzinga
CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
December 22, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
December 21, 2021
From
CytoDyn Inc.
Via
Business Wire
NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
December 13, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
December 09, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
December 08, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
December 01, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
November 29, 2021
From
CytoDyn Inc.
Via
Business Wire
Leronlimab (350 mg) Weekly Use for 14 Weeks in Open Label Arm of NASH Trial Produces Fibrosis Reduction as High as 93 msec Amongst First 15 Patients with Average Reduction of 24 msec
November 24, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Research Paper on Leronlimab Published in Frontiers in Immunology Journal
November 19, 2021
From
CytoDyn Inc.
Via
Business Wire
Health Canada Authorizes Emergency Use of Leronlimab for Treatment of First Triple-Negative Breast Cancer Patient in Canada
November 16, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Inc. Announces Adjournment of Annual Meeting of Shareholders to November 24, 2021 Due to Lack of Quorum
October 28, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Announces Delaware Court Has Denied Activist Group’s Motion to Prevent Annual Meeting from Taking Place
October 20, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn Alerts Shareholders to Vote on Company’s Proxy Card Ahead of October 28th Annual Meeting
October 18, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Comments on Delaware Court Decision
October 14, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
Delaware Court Agrees with CytoDyn that Activist Group’s Nominations are Invalid
October 14, 2021
From
CytoDyn Inc.
Via
Business Wire
These OTC Markets Securities had the Most Trading Activity in September
October 12, 2021
Photo by Annie Spratt on Unsplash As the 3rd quarter came to a close in September, the OTC Markets saw a slight decrease in total trading volume even as companies reported...
Via
Benzinga
CytoDyn Comments on Rosenbaum/Patterson Activist Group “Plan”
September 29, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Releases White Paper Regarding Company’s Extremely Unfavorable Borrowing Practices
September 27, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
October 07, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 6) Enanta Pharmaceuticals, Inc...
Via
Benzinga
CytoDyn to Present at Emerging Growth Conference on September 29 Followed by Live Q/A
September 27, 2021
From
CytoDyn Inc.
Via
Business Wire
Group of CytoDyn Stockholders Shares Strategic Plan to Obtain Cancer Therapy Approval for Leronlimab
September 24, 2021
From
Gasthalter & Co. on behalf of CytoDyn Inc. shareholders
Via
Business Wire
CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to Commence a Pivotal Phase 3 Trial in Critically Ill COVID-19 Patients with IV Administration of Four Doses (700mg/week)
September 22, 2021
From
CytoDyn Inc.
Via
Business Wire
CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at the World Antiviral Congress 2021
September 21, 2021
From
CytoDyn Inc.
Via
Business Wire
Accelerated Development of COVID-19 Vaccines to Combat Potential for Possible Future Viral Pathogens and Variants
September 22, 2021
Via
FinancialNewsMedia
Exposures
COVID-19
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.